PMID- 23283820
OWN - NLM
STAT- MEDLINE
DCOM- 20140701
LR  - 20220330
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 44
IP  - 2
DP  - 2013 Oct
TI  - Impact of incretin on early-phase insulin secretion and glucose excursion.
PG  - 403-10
LID - 10.1007/s12020-012-9867-9 [doi]
AB  - This study investigated the impact of incretin on early-phase insulin secretion 
      and glucose excursion. The normal glucose tolerance (NGT), impaired glucose 
      tolerance (IGT), and type 2 diabetes mellitus (T2DM) groups included 16, 8, and 
      19 subjects, respectively. Subjects underwent continuous glucose monitoring for 3 
      days, followed by an oral glucose tolerance test. Plasma glucose, insulin, 
      glucagon, total glucose-dependent insulinotropic polypeptide (GIP), and 
      glucagon-like peptide-l (GLP-1) levels were measured at 30-min increments for 2 h 
      after glucose intake. Differences with P < 0.05 were considered statistically 
      significant. The area under the curve (AUC) of total GIP (120-min GIP-AUC) of the 
      T2DM group was significantly lower than those of the NGT and IGT groups. The 
      120-min GLP-1-AUC of the NGT group was significantly larger than those of the 
      T2DM and IGT groups. The early-phase insulin secretion index (DeltaI30/DeltaG30) of the 
      T2DM group was significantly lower than those of the NGT and IGT groups. Mean 
      amplitudes of glycemic excursions (MAGEs) went in the order of NGT < IGT < T2DM 
      (P < 0.01, IGT vs. NGT; P < 0.001, T2DM vs. IGT). The 120-min GIP-AUC was 
      negatively correlated with MAGE (r = -0.464), but uncorrelated with DeltaI30/DeltaG30. 
      The 120-min GLP-1-AUC was positively correlated with DeltaI30/DeltaG30 (r = 0.580), but 
      negatively correlated with MAGE (r = -0.606). Incretin may ameliorate glucose 
      excursions, and GLP-1 may exert them by promoting early-phase insulin secretion. 
      No correlation was observed between GIP secretion and early-phase insulin 
      secretion.
FAU - Shen, Jie
AU  - Shen J
AD  - Department of Endocrinology, The Third Affiliated Hospital of Southern Medical 
      University, 183 Zhongshan Road West, Guang Zhou, 510630, People's Republic of 
      China, shenjiedr@163.com.
FAU - Chen, Zhi
AU  - Chen Z
FAU - Chen, Chaofeng
AU  - Chen C
FAU - Zhu, Xiao
AU  - Zhu X
FAU - Han, Yajuan
AU  - Han Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130103
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Blood Glucose)
RN  - 0 (Incretins)
RN  - 0 (Insulin)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Adult
MH  - Blood Glucose/*metabolism
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/blood
MH  - Female
MH  - Gastric Inhibitory Polypeptide/blood
MH  - Glucagon/blood
MH  - Glucagon-Like Peptide 1/blood
MH  - Glucose Intolerance/blood
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Incretins/*blood/*physiology
MH  - Insulin/blood/*metabolism
MH  - Insulin Secretion
MH  - Male
MH  - Middle Aged
EDAT- 2013/01/04 06:00
MHDA- 2014/07/02 06:00
CRDT- 2013/01/04 06:00
PHST- 2012/04/12 00:00 [received]
PHST- 2012/12/11 00:00 [accepted]
PHST- 2013/01/04 06:00 [entrez]
PHST- 2013/01/04 06:00 [pubmed]
PHST- 2014/07/02 06:00 [medline]
AID - 10.1007/s12020-012-9867-9 [doi]
PST - ppublish
SO  - Endocrine. 2013 Oct;44(2):403-10. doi: 10.1007/s12020-012-9867-9. Epub 2013 Jan 
      3.